Technology
Health
Pharmaceutical

Adial Pharmaceuticals

$3.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.10 (-3.22%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ADIL and other stocks, options, ETFs, and crypto commission-free!

About

Adial Pharmaceuticals, Inc Common Stock, also called Adial Pharmaceuticals, is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. Read More The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.

Employees
Headquarters
Charlottesville, Virginia
Founded
2010
Market Cap
20.66M
Price-Earnings Ratio
Dividend Yield
Average Volume
785.47K
High Today
$3.13
Low Today
$2.85
Open Price
$3.10
Volume
93.27K
52 Week High
$9.44
52 Week Low
$1.11

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Alcohol
Beverages
Food

News

Simply Wall StFeb 23

How Do Analysts See Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Performing In The Next Couple Of Years?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The latest earnings release Adial Pharmaceuticals, Inc.’s (NASDAQ:ADIL) announced in December 2018 revealed company earnings became less negative compared to the previous year’s level – great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts view Adial Pharmaceuticals’s earnings growth outlook over the next few years and whether the future looks...

506
StreetInsiderFeb 20

Adial Pharmaceuticals (ADIL) Partners with Catalent to Package & Distribute AD04 for Phase 3 Trial

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) today announced a partnership with Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, to advance clinical activities related to AD04, Adial’s genetically targeted, lead investigational new drug product for the treatment of alcohol use disorder (“AUD”). This partnership brings together critical capabilities to allow the commencement of Adial’s planned ini...

228

Earnings

-$1.48
-$1.05
-$0.61
-$0.18
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.